Fairvalue-Calculator Fairvalue-Calculator
EN DE

GenMont Biotech Incorporation (3164) Fair Value & Analysis

Healthcare · TW · Market cap 1.4B TWD

Price16.25 TWD
Fair Value13.15 TWD
Upside-19.1%
Quality84/100
Evidence: Medium Range 9.27 TWD – 17.45 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

GenMont Biotech Incorporation (3164) currently trades at 16.25 TWD, while our model-based Fair Value estimate is 13.15 TWD — implying the stock looks roughly 19.1% overvalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is GenMont Biotech Incorporation (3164) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 13.15 TWD versus a price of 16.25 TWD — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 3164?
Our 21-model fair value for GenMont Biotech Incorporation is 13.15 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 16.25 TWD.
What is the quality score of 3164?
GenMont Biotech Incorporation has a Quality Score of 84/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.